---
id: leishmaniasis-treatment_259
category: antimicrobials
tags: [antiprotozoal, leishmaniasis, amphotericin, miltefosine, CDC-guidelines]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Leishmaniasis Treatment: FDA-Approved Agents

**Q:** What are the FDA-approved treatments for visceral and cutaneous leishmaniasis in the United States, including dosing regimens?

**A:**

| Drug | FDA Approval | Indications | Dosing |
|------|--------------|-------------|--------|
| **Liposomal amphotericin B (AmBisome)** | VL + CL | *All Leishmania spp.* | **VL (immunocompetent):** 3 mg/kg IV days 1-5, 14, 21 (total 21 mg/kg)<br>**VL (immunosuppressed):** 4 mg/kg IV days 1-5, 10, 17, 24, 31, 38 (total 40 mg/kg)<br>**CL:** 3 mg/kg IV daily × 6-10 doses |
| **Miltefosine (oral)** | 2014 (VL, CL, ML) | Age ≥12 yrs, ≥30 kg, specific *Leishmania* species | Weight-based dosing × 28 days |

**Efficacy:**
- Liposomal amphotericin B: **≥90% cure rate** for VL
- Miltefosine: **94% cure rate** for VL (ITT analysis 282/299)

**WHO Combination Therapy:**
- Liposomal amphotericin B + miltefosine for VL (synergistic)

**Key Pearl:** Liposomal formulation has **less nephrotoxicity** than conventional amphotericin B.

**Media:**

**Sources:** [CDC Leishmaniasis Clinical Care], [IDSA/ASTMH Leishmaniasis Guidelines CID 2016], [PMC2376078 - Miltefosine Evidence], [Medscape Leishmaniasis Treatment]
